AIDS Therapies (GEM 91)

Decreases in Cellular Viremia Observed in HIV Positive Patients

Published in AIDS Weekly, April 21st, 1997

Hybridon, Inc., Cambridge, Massachusetts, reported the unblinded results of the three highest dose levels of its Phase Ib/II clinical trial of GEM 91.

GEM 91 is a genetic antisense drug designed to attack the HIV genome. The analysis revealed a substantial decrease in cellular viremia levels of up to 1.3 logs (90 percent reduction) in HIV positive-patients treated with GEM 91 after eight days (a log is a 10-fold change). The company also reported it is conducting a Phase II confirmatory clinical study of GEM 91 at multiple clinical centers in the US and Puerto Rico in order to confirm these results.

The unblinded data were collected on 22 HIV...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1997-04-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry